Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$3.20 USD
+0.06 (1.91%)
Updated Sep 11, 2024 01:47 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Lisata Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 51 | 69 | 95 | 35 | 25 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 3 | 1 | 1 | 1 |
Total Current Assets | 54 | 72 | 96 | 35 | 26 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 1 | 1 | 1 |
Total Assets | 55 | 73 | 97 | 36 | 27 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 3 | 2 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 4 | 3 | 2 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 7 | 6 | 5 | 4 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 7 | 7 | 5 | 4 | 7 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 577 | 575 | 546 | 459 | 439 |
Retained Earnings | -528 | -507 | -453 | -426 | -417 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 1 | 1 | 1 | 1 | 1 |
Total Shareholder's Equity | 48 | 66 | 92 | 32 | 21 |
Total Liabilities & Shareholder's Equity | 55 | 73 | 97 | 36 | 27 |
Total Common Equity | 48 | 66 | 92 | 32 | 21 |
Shares Outstanding | 8.10 | 7.80 | 3.90 | 2.20 | 0.60 |
Book Value Per Share | 5.91 | 8.50 | 23.59 | 14.65 | 34.25 |
Fiscal Year End for Lisata Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 38 | 43 | 51 | 54 | 58 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 4 | 3 | 3 | 4 |
Total Current Assets | 42 | 48 | 54 | 57 | 61 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 43 | 48 | 55 | 58 | 62 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 2 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 4 | 4 | 4 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 4 | 5 | 7 | 5 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5 | 6 | 7 | 5 | 5 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 578 | 577 | 577 | 576 | 576 |
Retained Earnings | -539 | -533 | -528 | -523 | -517 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 1 | 1 | 1 | 1 | 1 |
Total Shareholder's Equity | 38 | 43 | 48 | 53 | 58 |
Total Liabilities & Shareholder's Equity | 43 | 48 | 55 | 58 | 62 |
Total Common Equity | 38 | 43 | 48 | 53 | 58 |
Shares Outstanding | 8.30 | 8.30 | 8.10 | 8.10 | 7.90 |
Book Value Per Share | 4.58 | 5.15 | 5.91 | 6.51 | 7.31 |